- Amwell (NYSE: AMWL) is a leading provider of a comprehensive SaaS-based software platform designed for technology-enabled healthcare, offering unified access to diverse clinical programs for payers and health systems.
- In February 2026, Amwell announced its fourth quarter and full year 2025 operating results, showcasing its ongoing commitment to transparency and stakeholder engagement.
- Amwell's platform powers numerous clinical programs and has established partnerships with various health systems and payers to enhance patient access to care.
- The ideal buyers for Amwell are healthcare payers and systems looking to improve patient access and streamline care delivery, making it crucial for sales teams to engage as demand for telehealth solutions continues to rise.
Engineering is Amwell’s largest department at about 264 employees, highlighting the continued importance of product development and platform reliability in the company’s strategy. Clinical and patient-facing work is represented by roughly 198 employees in Healthcare, while Sales and Support accounts for about 118 people who focus on customer acquisition and satisfaction. Marketing and Product (99 employees), Business Management (81), Operations (73), Finance and Administration (40), and a collection of smaller specialty teams—including Risk, Safety & Compliance—round out the organizational structure. The distribution suggests a technology-centric company that also maintains sizeable clinical and go-to-market functions.
Amwell maintains a hybrid and distributed footprint. Approximately 218 employees work from the Boston headquarters, while another 320 people are spread across established hubs such as Washington, DC; New York; Los Angeles; San Francisco; Seattle; Philadelphia; Portland; and Tel Aviv. The remaining 660 employees fall into an “Other” category that includes fully remote staff and smaller satellite locations, underscoring the company’s flexibility in sourcing talent wherever it is available.
